The novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cells

Leukemia

Volumn 27, Issue 11, 2013, Pages 2220-2228

  Garnier, N ^a,b   Petruccelli, L A ^a,b   Molina, M F ^a,b   Kourelis, M ^a,b   Kwan, S ^a,b   Diaz, Z ^a,b   Schipper, H M ^b   Gupta, A ^c   Del Rincon, S V ^a,b   Mann, K K ^a,b   Miller, W H ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Osta Biotechnologies Inc   (Canada)

Author keywords

arsenic; BRG1; Darinaparsin; HO 1; leukemia; NRF2

Indexed keywords

ARSENIC TRIOXIDE; BRG1 PROTEIN; DARINAPARSIN; HEME OXYGENASE 1; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL PROTECTION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOTOXICITY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; ARSENICALS; BLAST CRISIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CYTOPROTECTION; DNA HELICASES; FLOW CYTOMETRY; GLUTATHIONE; HEME OXYGENASE-1; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NF-E2-RELATED FACTOR 2; NUCLEAR PROTEINS; OXIDES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84887316671     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.54     Document Type: Article

References (39)

1. Mann KK, Wallner B, Lossos IS, Miller Jr. WH. Darinaparsin: a novel organic arsenical with promising anticancer activity. Exp Opin Investig Drugs 2009; 18: 1727-1734.
2. Diaz Z, Mann KK, Marcoux S, Kourelis M, Colombo M, Komarnitsky PB et al. A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia 2008; 22: 1853-1863.
3. Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N, Yagi K. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and downregulation of Bcl-2 protein. Br J Haematol 1998; 102: 1055-1060. (Pubitemid 28410539)
4. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB et al. Arsenic trioxidemediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000; 6: 4957-4964. (Pubitemid 32110442)
5. Hyun Park W, Hee Cho Y, Won Jung C, Oh Park J, Kim K, Hyuck ImY et al. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 2003; 300: 230-235. (Pubitemid 36042957)
6. Camacho LHHD, Gutierrez C, Vertovsek S, Tannir N, Parker CA, Purdom MA et al. Phase-1 trial of ZIO-101, a novel organic arsenic in patients with advanced cancers (abstract). J Clin Oncol 2006; 24: p 605S.
7. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277. (Pubitemid 29019412)
8. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-2111. (Pubitemid 29430427)
9. Lee TC, Wei ML, Chang WJ, Ho IC, Lo JF, Jan KY et al. Elevation of glutathione levels and glutathione S-transferase activity in arsenic-resistant Chinese hamster ovary cells. In Vitro Cell Dev Biol 1989; 25: 442-448. (Pubitemid 19158904)
10. Ochi T, Kaise T, Oya-Ohta Y. Glutathione plays different roles in the induction of the cytotoxic effects of inorganic and organic arsenic compounds in cultured BALB/c 3T3 cells. Experientia 1994; 50: 115-120. (Pubitemid 24086624)
11. Davison K, Cote S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003; 17: 931-940. (Pubitemid 36626322)
12. Ninomiya M, Kajiguchi T, Yamamoto K, Kinoshita T, Emi N, Naoe T. Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy. Haematologica 2006; 91: 1571-1572. (Pubitemid 44736130)
13. Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, Naoe T. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sci 2006; 97: 540-545. (Pubitemid 43811597)
14. Davison K, Mann KK, Waxman S, Miller Jr. WH. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004; 103: 3496-3502. (Pubitemid 38525683)
15. Copple IM, Goldring CE, Kitteringham NR, Park BK. The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology 2008; 246: 24-33.
16. Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 2010; 50: 323-354.
17. Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA 1994; 91: 9926-9930. (Pubitemid 24311921)
18. Nioi P, McMahon M, Itoh K, Yamamoto M, Hayes JD. Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem J 2003; 374(Pt 2): 337-348. (Pubitemid 37094093)
19. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999; 13: 76-86. (Pubitemid 29045117)
20. Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 2005; 25: 162-171. (Pubitemid 40039808)
21. McMahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 2003; 278: 21592-21600. (Pubitemid 36792558)
22. Reichard JF, Sartor MA, Puga A. BACH1 is a specific repressor of HMOX1 that is inactivated by arsenite. J Biol Chem 2008; 283: 22363-22370.
23. Zhang J, Ohta T, Maruyama A, Hosoya T, Nishikawa K, Maher JM et al. BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress. Mol Cell Biol 2006; 26: 7942-7952. (Pubitemid 44630994)
24. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313-322. (Pubitemid 27373291)
25. Blank V, Kim MJ, Andrews NC. Human MafG is a functional partner for p45 NF-E2 in activating globin gene expression. Blood 1997; 89: 3925-3935. (Pubitemid 27220935)
26. Reichard JF, Motz GT, Puga A. Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res 2007; 35: 7074-7086.
27. Walker AM, Stevens JJ, Tchounwou PB. Arsenic trioxide modulates dna synthesis and apoptosis in lung carcinoma cells. Met Ions Biol Med 2010; 7: 1996-2007.
28. Sif S, Stukenberg PT, Kirschner MW, Kingston RE. Mitotic inactivation of a human SWI/SNF chromatin remodeling complex. Genes Dev 1998; 12: 2842-2851. (Pubitemid 28440143)
29. Muchardt C, Reyes JC, Bourachot B, Leguoy E, Yaniv M. The hbrm and BRG-1 proteins, components of the human SNF/SWI complex, are phosphorylated and excluded from the condensed chromosomes during mitosis. EMBO J. 1996; 15: 3394-3402. (Pubitemid 26231946)
30. Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ et al. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci USA 2008; 105: 10762-10767.
31. Matsuoka S, Ballif BA, Smogorzewska A, McDonald 3rd ER, Hurov KE, Luo J et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316: 1160-1166. (Pubitemid 46877472)
32. Alaoui-Jamali MA, Bismar TA, Gupta A, Szarek WA, Su J, Song W et al. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res 2009; 69: 8017-8024.
33. Matulis SM, Morales AA, Yehiayan L, Croutch C, Gutman D, Cai Y et al. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther 2009; 8: 1197-1206.
34. Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK et al. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res 2009; 15: 4769-4776.
35. Schou KB, Schneider L, Christensen ST, Hoffmann EK. Early-stage apoptosis is associated with DNA-damage-independent ATM phosphorylation and chromatin decondensation in NIH3T3 fibroblasts. Cell Biol Int 2008; 32: 107-113. (Pubitemid 351249146)
36. Platanias LC. Biological responses to arsenic compounds. J Biol Chem 2009; 284: 18583-18587.
37. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 2006; 86: 583-650.
38. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 2002; 99: 16093-16098. (Pubitemid 35462754)
39. D'Autreaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 2007; 8: 813-824. (Pubitemid 47462134)